Replimune Group, Inc. (NASDAQ:REPL) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

Replimune Group, Inc. (NASDAQ:REPL) has earned an average recommendation of “Moderate Buy” from the ten brokerages that are currently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $12.00.

REPL has been the topic of several research reports. Weiss Ratings cut shares of Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 11th. Wedbush raised shares of Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 price objective for the company in a research note on Friday, August 7th. BMO Capital Markets upgraded shares of Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 target price on the stock in a report on Tuesday, June 30th. Leerink Partners upgraded shares of Replimune Group from a “market perform” rating to an “outperform” rating and upped their target price for the company from $11.00 to $17.00 in a research report on Tuesday, August 4th. Finally, Wolfe Research raised shares of Replimune Group to an “outperform” rating in a report on Tuesday, August 4th.

Insider Buying and Selling

In other Replimune Group news, insider Konstantinos Xynos sold 11,447 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $148,467.59. Following the sale, the insider directly owned 224,215 shares of the company’s stock, valued at $2,908,068.55. The trade was a 4.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Sushil Patel sold 39,341 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $12.97, for a total value of $510,252.77. Following the sale, the chief executive officer owned 708,151 shares in the company, valued at approximately $9,184,718.47. This trade represents a 5.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 79,124 shares of company stock valued at $1,038,364. Insiders own 5.40% of the company’s stock.

Hedge Funds Weigh In On Replimune Group

Large investors have recently modified their holdings of the stock. AXQ Capital LP raised its position in shares of Replimune Group by 4.1% during the 2nd quarter. AXQ Capital LP now owns 27,121 shares of the company’s stock worth $300,000 after purchasing an additional 1,056 shares during the last quarter. Walleye Capital LLC lifted its stake in Replimune Group by 3.2% in the 1st quarter. Walleye Capital LLC now owns 71,592 shares of the company’s stock valued at $548,000 after buying an additional 2,192 shares in the last quarter. Allworth Financial LP acquired a new stake in Replimune Group in the 2nd quarter worth about $62,000. Essential Partners LLC boosted its holdings in Replimune Group by 562,400.0% in the 1st quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock worth $43,000 after buying an additional 5,624 shares during the last quarter. Finally, Legal & General Group Plc acquired a new stake in Replimune Group in the 2nd quarter worth about $85,000. Institutional investors own 92.53% of the company’s stock.

Replimune Group Stock Performance

REPL opened at $11.05 on Tuesday. The firm has a 50-day simple moving average of $13.78 and a two-hundred day simple moving average of $9.78. The company has a debt-to-equity ratio of 1.00, a current ratio of 5.23 and a quick ratio of 5.23. Replimune Group has a 52 week low of $1.50 and a 52 week high of $16.33.

Replimune Group (NASDAQ:REPL) last issued its earnings results on Friday, August 14th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.03). Equities analysts predict that Replimune Group will post -2.82 EPS for the current year.

About Replimune Group

Replimune Group, Inc is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for the treatment of cancer. The company’s approach uses genetically engineered viruses designed to selectively replicate in tumors, directly destroy cancer cells and stimulate a broader immune response against malignant tissue.

Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 intended for use in patients with advanced solid tumors.